Chinese milestone for Frontier

7 June 2018
2019_biotech_test_vial_discovery_big

Frontier Biotechnologies is responsible for reaching market with the first new HIV medicine discovered and developed in China.

The Chinese company has received marketing authorization from the China Food and Drug Administration for Aikening (albuvirtide for injection, ABT) for the treatment of HIV-1.

ABT is a new chemical entity with a novel molecular mechanism of action and long-acting activity against HIV-1. It has been approved for use in treatment-experienced adults who still have virus replication, in combination with other antiretroviral agents.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology